All In MedTech

Device Trial Radar · NCT02607527

Annular Reshaping of the Mitral Valve for Patients With Mitral Regurgitation Using the Millipede IRIS System

Last checked: Nov 20, 2026Latest source record: Oct 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

21

Actual

Start

May 8, 2017

Primary completion

Jan 17, 2019

Study completion Dec 19, 2019

Sponsor

Lead sponsor
Boston Scientific CorporationPublic (BSX)
Sponsor type
Industry
First posted
Nov 18, 2015

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Device feasibility
FDA-regulated device
Yes
Who can join
All sexes, from 30 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multi center evaluation of the Millipede IRIS for treatment of clinically significant mitral regurgitation in subjects determined appropriate for mitral valve surgery.

Conditions

  • Mitral Valve Insufficiency

Interventions

  • Mitral Valve IRIS RingDevice

    Transcatheter implantation of the IRIS

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Acute Safety defined as incidence of adverse eventsTime frame: Procedure through 30 days post procedure

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Dante Pazzanese de Cardiologia

    São Paulo, Brazil

1 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.